Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon

Virology Journal

Volumn 4, Issue , 2007, Pages

  Hazari, Sidhartha ^a   Taylor, Lizeth ^b,c   Haque, Salima ^a   Garry, Robert F ^a   Florman, Sander ^a   Luftig, Ronald ^b   Regenstein, Frederic ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; JANUS KINASE 1; JANUS KINASE 2; RECOMBINANT ALPHA2B INTERFERON; RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; STAT2 PROTEIN, HUMAN; TYK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CELL CLONE; CELL CULTURE; CONTROLLED STUDY; GENE ACTIVATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPLICON; SIGNAL TRANSDUCTION; VIRUS CULTURE; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; JANUS KINASE 1; PHOSPHORYLATION; RNA, VIRAL; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TYK2 KINASE; VIRAL PROTEINS;

EID: 36049014040     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-89     Document Type: Article

References (46)

1. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. HJ Alter LB Seeff, Seminar Liver Disease 2000 20 17 35 10.1055/s-2000-9505
2. Medical progress: hepatitis C virus infection. G Lauer B Walker, New Eng J Med 2001 345 41 52 10.1056/NEJM200107053450107 11439948
3. Epidemiology of hepatitis C. MJ Alter, Hepatology 1997 26 62S 65S 10.1002/hep.510260711 9305666
4. Pathogenesis, natural history, treatment, and prevention of hepatitis C. TJ Liang B Rehermann LB Seeff JH Hoofnagle, Ann Intern Med 2000 132 296 305 10681285
5. Hepatocellular carcinoma: Summary and recommendation. JH Hoofnagle, Gastroenterology 2004 127 S319 S323 10.1053/j.gastro.2004.09.047 15508100
6. Hepatocellular carcinoma: recent trends in the United States. HB El-Serag, Gastroenterology 2004 127 S27 34 10.1053/j.gastro.2004.09.013 15508094
7. Current therapy for chronic hepatitis C. GL Davis, Gastroenterology 2000 118 S104 114 10.1016/S0016-5085(00)70009-6 10868901
8. Hepatitis C and liver transplantation. RS Brown, Nature 2005 436 973 978 10.1038/nature04083 16107838
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. GL Davis R Esteban-Mur V Rustgi J Hoefs SC Gordon C Trepo ML Shiffman S Zeuzem A Craxi MH Ling J Albrecht, N Engl J Med 1998 339 1493 1499 10.1056/NEJM199811193392102 9819447
10. Peginterferon alpfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 58 958 965 10.1016/S0140-6736(01)06102-5
11. Mechanism of action of interferon and ribavirin treatment of hepatitis C. JJ Feld JH Hoofnagle, Nature 2005 436 967 972 10.1038/nature04082 16107837
12. Diagnosis, management, and treatment of hepatitis C. DB Strader T Wright DL Thomas LB Seeff American Association for the Study of Liver Diseases, Hepatology 2004 39 1147 1171 10.1002/hep.20119 15057920
13. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr D Haussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu, New Eng J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
14. Genetic diversity and evolution of hepatitis C virus-15 years on. P Simmonds, J Gen Virol 2004 85 3173 88 10.1099/vir.0.80401-0 15483230
15. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. J Bukh RH Miller RH Purcell, Semin Liver Dis 1995 15 41 63 7597443
16. Overview of hepatitis C virus genome structure, polyprotein processing and protein properties. KE Reed CM Rice, Curr Top Microbiol Immunol 2000 242 55 84 10592656
17. The nature of interferon-alpha resistance in hepatitis C virus infection. JM Pawlotsky, Current Opinion on Infectious Disease 2003 16 587 592 10.1097/00001432-200312000-00012
18. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. JM Pawlotsky, Antiviral Research 2003 59 1 11 10.1016/S0166- 3542(03)00088-3 12834855
19. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. N Enomoto I Sakuma Y Asahina M Kurosaki T Murakami C Yamamoto N Izumi F Marumo C Sato, Journal of Clinical Investigation 1995 96 224 230 7542279
20. Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Enomoto I Sakuma Y Asahina M Kurosaki T Murakami C Yamamoto Y Ogura N Izumi F Marumo C Sato, New Eng J Med 1996 334 77 81 10.1056/NEJM199601113340203 8531962
21. Hepatitis C virus NS5A protein inhibits interferon antiviral activity but the effects do not correlate with clinical response. M Paterson CD Laxton HC Thomas AM Ackrill GR Foster, Gastroenterology 1999 117 1187 1197 10.1016/S0016-5085(99)70405-1 10535883
22. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. WP Hoffmann S Zeuzem C Sarrazin, Journal of Clinical Virology 2005 32 86 91 10.1016/j.jcv.2004.08.004 15653410
23. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. J Schinkel WJ Spoon AC Kroes, Antiviral Therapy 2004 9 275 286 15134190
24. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Nousbaum SJ Polyak SC Ray DG Sullivan AM Larson RL Carithers DR Gretch, Journal of Virology 2000 74 9028 9038 10982347 10.1128/JVI.74.19.9028-9038.2000
25. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. MJ Gale Jr MJ Korth NM Tang SL Tan DA Hopkins TE Dever SJ Polyak DR Gretch MG Katze, Virology 2000 230 217 227 10.1006/viro.1997.8493
26. Control of PKR protein kinase by hepatitis C virus non-structural 5A protein: Molecular mechanisms of kinase regulation. M Gale CM Blakely B Kwieciszewski SL Tan M Dossett NM Tang MJ Korth SJ Polyak DR Gretch MG Katze, Molecular and Cellular Biology 1997 18 5208 5218
27. Inhibition of the interferon-inducible protein kinase R by HCV E2 protein. DR Taylor ST Shi PR Romano GN Barber MM Lai, Science 1999 285 107 109 10.1126/science.285.5424.107 10390359
28. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. A Blindenbacher FH Duong L Hunziker ST Stutvoet X Wang L Terracciano D Moradpour HE Blum T Alonzi M Tripodi N La Monica MH Heim, Gastroenterology 2003 124 1465 1475 10.1016/S0016-5085(03)00290- 7 12730885
29. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. C François G Duverlie D Rebouillat H Khorsi S Castelain HE Blum A Gatignol C Wychowski D Moradpour EF Meurs, Journal of Virology 2003 74 5587 5596 10.1128/JVI.74.12.5587-5596.2000
30. Expression of HCV structural proteins impairs IFN-mediated antiviral response. P Keskinen K Melen I Julkunen, Virology 2003 299 164 171 10.1006/viro.2002.1527
31. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. W Lin WH Choe Y Hiasa Y Kamegaya JT Blackard EV Schmidt RT Chung, Gastroenterology 2005 128 1034 1041 10.1053/j.gastro.2005.02.006 15825084
32. Evasion of intracellular host defence by hepatitis C virus. M Gale EM Foy, Nature 2005 436 939 945 10.1038/nature04078 16107833
33. Innate Immune recognition of viral infection. T Kawai S Akira, Nature Immunol 2006 7 131 137 10.1038/ni1303
34. Genetic transfer of a functional human interferon alpha-receptor into mouse cells: cloning and expression of its cDNA. G Uze G Lutfalla I Gresser, Cell 1990 60 225 234 10.1016/0092-8674(90)90738-Z 2153461
35. Studies of interferon-induced transcriptional activation uncover the Jak-STAT pathway. JE Darnell Jr, J of Interf and Cytok Res 1998 18 549 554
36. Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. S Goodbourn L Didcock RE Randall, J of Gen Virol 2000 81 2341 2364
37. Activation of interferon stimulated response element (ISRE) in Huh-7 cells replicating HCV subgenomic RNA. M Pai R Prabhu A Panebra S Nangle S Haque F Bastian R Garry K Agrawal S Goodbourn S Dash, Intervirology 2005 48 301 311 10.1159/000085099 15956798
38. Interferons alpha, beta, gamma each inhibits hepatitis C virus replication at the level internal ribosome entry site mediated translation. S Dash R Prabhu S Hazari F Bastian R Garry W Zou S Haque V Joshi FG Regenstein SN Thung, Liver International 2005 25 580 94 10.1111/j.1478-3231.2005.01082.x 15698392
39. Racial differences in responses to therapy with interferon in chronic hepatitis c. Consensus Interferon Study Group. KR Reddy JH Hoofnagle MJ Tong, Hepatology 1999 30 787 793 10.1002/hep.510300319 10462387
40. Host factors and failure of interferon alpha treatment in hepatitis C virus. B Gao F Hong S Radaeva, Hepatology 2004 39 880 890 10.1002/hep.20139 15057887
41. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. R Sumpter Jr C Wang E Foy YM Loo M Gale Jr, J of Virol 2004 78 11591 11604 10.1128/JVI.78.21.11591-11604.2004
42. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype. K Namba K Naka H Dansako A Nozaki M Ikeda Y Shiratori K Shimotohno N Kato, Biochem and Biophys Res Comm 2004 323 299 309 10.1016/j.bbrc.2004.08.091
43. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type1 interferon receptors. K Naka K Takemoto K Abe H Dansako M Ikeda K Shimotohno N Kato, J of Gen Virol 2005 86 2787 2792 10.1099/vir.0.81124-0
44. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. H Zhu D Nelson JM Crawford C Liu, J of Interf and Cytok Res 2005 25 528 539 10.1089/jir.2005.25.528
45. 125I-interferon-alpha binding to peripheral blood cells from African-Americans and Caucasians with hepatitis C. P Kimball S Verbeke M Shiffman, J Viral Hepat 2003 10 354 9 10.1046/j.1365-2893.2003.00444.x 12969187
46. Interaction of interferon with cellular receptors: internalizationand degradation of cell-bound interferon. A Branca C Faltynek Alessandro D C Baglioni, J Biol Chem 1982 257 13291 13296 6292184